integrity and efficacy.

In each case, the product stability analysis pointed towards potential chemical migration from the BFS containers. Such signals prompted the quality assurance (QA) team to initiate an immediate review of packaging systems, focusing particularly on the extractables and leachables studies.

Likely Causes (by category)

The QA team utilized the 5-Why technique to categorize potential sources of leachable contamination. The possible causes emerged as follows:

Category	Likely Causes
Materials	Suboptimal grade of polymer resins used in BFS containers.
Method	Improper cleaning validation of manufacturing equipment prior to filling.
Machine	Inadequate equipment maintenance leading to process variations.
Man	Lack of training on handling and storing BFS containers.
Measurement	Insufficient testing methods not capable of detecting all leachables.
Environment	Exposure to elevated temperatures during storage and handling.

Immediate Containment Actions (first 60 minutes)

Recognizing the urgency presented by the elevated leachables, the company took immediate containment actions within the first hour:

• Quarantined the affected batches to prevent distribution.
• Conducted an emergency review of the batch records for the affected products.
• Communicated with the suppliers of BFS containers to assess previous extractables data.
• Initiated immediate stability testing on new batches filled in alternative containers.

Investigation Workflow (data to collect + how to interpret)

The investigation required a systematic approach to data collection and analysis. The following steps were taken:

• Gathering Historical Data: Reviewed historical extractables data from previous compatibility testing.
• Batch Record Review: Examined filling and storage conditions documented in batch records for discrepancies.
• Leachables Testing: Conducted a focused leachables assessment using gas chromatography-mass spectrometry (GC-MS) to identify potential leachables and their concentration levels.
• Environmental Monitoring: Collected environmental data such as temperature and humidity levels during processing and storage.

Using this data, the QA and regulatory teams could correlate the increased leachables with specific batches and formulations, guiding further investigation.

Root Cause Tools (5-Why, Fishbone, Fault Tree) and when to use which

In addressing the underlying issues, several root cause analysis (RCA) tools were employed:

• 5-Why: Ideal for identifying deeper causes behind a single issue, the team used this to explore why elevated leachables occurred. For instance, “Why was there discoloration?” could lead to subsequent inquiries into material and environmental factors.
• Fishbone Diagram: Useful for visualizing potential causes across various categories (materials, methods, human factors, etc.). The team mapped each cause as identified in the earlier symptoms section.
• Fault Tree Analysis: Employed to understand the failure modes of the BFS containers. This tool allowed the investigation to systematically analyze how one failure might lead to another, helping to pinpoint the pathways to contamination.

CAPA Strategy (correction, corrective action, preventive action)

The response to the elevated extractables levels focused on a comprehensive CAPA strategy involving:

• Correction: Immediate measures were taken to evaluate leachables profiles of all BFS containers in use, halting production in impacted areas.
• Corrective Action: Implemented stricter qualification criteria for all BFS supplies. The team mandated rigorous extractables and leachables studies to be conducted for any new or modified packaging components.
• Preventive Action: Enhanced training modules for employees on materials handling, potential contamination scenarios, and utilizing optimal storage conditions to prevent chemical migration.

Control Strategy & Monitoring (SPC/trending, sampling, alarms, verification)

Following the implementation of CAPA, the packaging quality system was adjusted to incorporate a robust control strategy. The key elements included:

• Statistical Process Control (SPC): Utilized for real-time monitoring of leachables levels, with predetermined acceptable limits established based on chemical migration studies.
• Increased Sampling: Implemented additional sampling points during the filling process to catch deviations early.
• Alarms and Alerts: Integrated alarms into the monitoring systems to alert operators when chemical thresholds neared critical limits.
• Verification Methods: Established a continuous verification program to validate that leachables were within acceptable toxicology thresholds and regulatory limits.

Validation / Re-qualification / Change Control impact (when needed)

Given the impact of container changes on the leachables profile, the QA team planned:

Related Reads

• Packaging Failures Like Leaks and Mix-Ups? Practical Packaging System Solutions and Controls
• Pharmaceutical Packaging Systems – Complete Guide

• Validation: Conduct thorough validation of alternative BFS containers, including complete extractables and leachables studies.
• Re-qualification: Re-qualifying manufacturing processes surrounding the updated containers to ensure no adverse effects on product quality.
• Change Control: Implemented a strict change control procedure, mandating approvals for any alterations to materials, processes, or suppliers involved in the packaging chain.

Inspection Readiness: what evidence to show (records, logs, batch docs, deviations)

For successful regulatory inspections following the CAPA implementation, the company prepared comprehensive documentation including:

• Batch Records: Detailed records showcasing adherence to the new SOPs for packaging, including deviations and corrective actions taken.
• Raw Data: Lab reports documenting the results of all extractables and leachables studies, complete with analytical methodologies used.
• Training Records: Evidence from training sessions conducted to educate employees on new procedures and best practices.
• Change Control Documentation: Approved change requests associated with the new packaging standards and processes.

FAQs

What are extractables and leachables?

Extractables are compounds that can be released from a packaging system during manufacturing or storage—while leachables are those compounds that can migrate into the drug product over its shelf life.

Why are extractables and leachables studies important?

These studies are critical for ensuring patient safety and regulatory compliance by identifying any potential contaminants that may compromise the drug product’s quality.

How often should E&L studies be performed?

E&L studies should be performed upon any significant change in a packaging component, process, or manufacturing environment as defined in regulatory guidelines.

What methodologies are commonly used in E&L studies?

Common methodologies include GC-MS, HPLC, and FTIR for assessing both extractables and leachables profiles.

Who is responsible for conducting E&L studies?

The responsibility typically lies with the quality assurance team, in collaboration with regulatory affairs and production departments.

What are the regulatory expectations for E&L studies?

Regulators expect comprehensive risk assessments and validation data supporting the use of packaging materials, which should align with ICH guidelines and respective regulatory authority requirements.

Can E&L studies affect the product’s shelf life?

Yes, the outcomes of these studies can lead to changes in storage conditions, revised expiry dates, and alterations in product formulations to ensure safety and efficacy.

What is the impact of thermal conditions on E&L?

Higher temperatures can increase the rate of chemical migration from packaging materials, necessitating thorough assessments under stress conditions to ensure stability.

What documentation is essential for E&L compliance?

Documentation should include extractables and leachables study results, change control records, validation reports, and employee training certificates to demonstrate complete compliance.

How can companies prepare for regulatory inspections related to E&L?

Regularly review and update all related documentation, conduct internal audits, and ensure learning from previous inspections are integrated into practices to be adequately prepared.

What resources are available for E&L guidelines?

Resources such as the FDA’s guidance documents on E&L studies, ICH guidelines, and publications from organizations like the European Medicines Agency (EMA) provide insights into regulatory expectations and best practices.